

amended claims marked up to show the changes relative to the previous version thereof is attached hereto as **Exhibit A**. In addition, please add new claims 41-48 as follows.

--24. (Amended) A method for promoting wound healing in a

Applicants : Thomas M. Jessell et al.
Serial No. : Not Yet Known
Filed : November 2, 2001
Page 4

of dorsalin-1 polypeptide.--

a4
cont
--40. (Amended) A pharmaceutical composition for inhibiting the activity of dorsalin-1 polypeptide comprising an amount of the antibody of claim 38 effective to inhibit the activity of dorsalin-1 polypeptide and a pharmaceutically acceptable carrier.--

10002278-110201
--41. (New) A pharmaceutical composition comprising the isolated dorsalin-1 polypeptide of claim 17 or 19 and a pharmaceutically acceptable carrier.--

--42. (New) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to stimulate neural crest cell differentiation.--

--43. (New) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to regenerate a nerve cell in a subject.--

a5
--44. (New) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to promote bone growth in a subject.--

--45. (New) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to promote wound healing in a subject.--

--46. (New) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to